For the Inventor, By the Inventor

Enter inventor name

Erkki I Ruoslahti

Rancho Santa Fe, CA, United States of America

Erkki I Ruoslahti

USPTO Granted Patents = 133 (Patent Applications = 18)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 2.3

ph-index = 26

Forward Citations = 2,569(Granted Patents)

Forward Citations (Not Self Cited) = 2,314(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Rancho Sante Fe, CA (US) (1992 - 1999)
Olivenhain, CA (US) (1983 - 2001)
Ranco Santa Fe, CA (US) (2007)
San Diego, CA (US) (1997 - 2011)
San Francisdo, CA (US) (2013)
Bueuton, CA (US) (2013)
Busilton, CA (US) (2015)
Buelton, CA (US) (2016)
Buellton, CA (US) (2009 - 2022)
Rancho Santa Fe, CA (US) (1991 - 2024)
La Jolla, CA (US) (2010 - 2024)

Company Filing History:

La Jolla Cancer Research Foundation

Sanford-burnham Medical Research Institute

The Burnham Institute

4. 13 out of 88

Sanford Burnham Prebys Medical Discovery Institute

Burnham Institute for Medical Research

6. 7 out of 15,462

University of California

Vascular Biosciences

The Burnam Institute

La Jolla Cancer Research Center

La Jolla Cancer Research Institute

11. 1 out of 335

Kyungpook National University Industry-Academic Cooperation Foundation

Lisata Therapeutics, Inc.

13. 2 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 1983-2025

Loading Chart...

Loading Chart...

Areas of Expertise:

Cyclic Peptides

Targeted Delivery Systems

Tumor-Associated Macrophages

Peptide Homing

Alzheimer's Disease Detection

Nervous System Injuries

Atherosclerotic Plaques

Cancer Treatment

Rgd Peptides

Vascular Regulation

Fibrotic Disorders

Bladder Tumor Targeting

133 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12351653 - Pharmaceutical compositions comprising novel cyclic peptides (2025-07-08),

2. 12290569 - Methods and compositions using peptides and proteins with c-terminal elements (2025-05-06),

3. 12195558 - Targeted delivery system and methods of use therefor (2025-01-14),

4. 12023389 - Compositions that target tumor-associated macrophages and methods of use therefor (2024-07-02),

5. 11981752 - Tumor associated monocyte/macrophage binding peptide and methods of use thereof (2024-05-14),

6. 11642391 - Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same (2023-05-09),

7. 11571485 - Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof (2023-02-07),

8. 11571484 - Compositions that target tumor-associated macrophages and methods of use therefor (2023-02-07),

9. 11512110 - Targeted delivery system and methods of use therefor (2022-11-29),

10. 11458210 - Compounds and compositions for targeting brain injuries and methods of use thereof (2022-10-04),

11. 11376303 - Compositions and methods for treating nervous system injuries (2022-07-05),

12. 11260133 - Methods and compositions related to peptides and proteins with C-terminal elements (2022-03-01),

13. 11059718 - Methods and compositions using peptides and proteins with C-terminal elements (2021-07-13),

14. 10669311 - Targeted delivery system and methods of use therefor (2020-06-02),

15. 10653797 - Compounds and compositions for targeting brain injuries and methods of use thereof (2020-05-19),

Title: The Innovative Mind of Erkki I Ruoslahti

Introduction: Erkki I Ruoslahti, a distinguished inventor based in Rancho Santa Fe, CA (US), is renowned for his groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Erkki I Ruoslahti holds several patents in the areas of targeted drug delivery systems, cell adhesion molecules, and tumor microenvironment modulation, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning several decades, Erkki I Ruoslahti has made significant strides in the development of novel therapies for cancer treatment, particularly focusing on utilizing nanotechnology for precise drug delivery to tumor cells.

Collaborations: Throughout his career, Erkki I Ruoslahti has collaborated with leading research institutions, pharmaceutical companies, and biotechnology firms to further advance his pioneering research in the field of molecular medicine.

Conclusion: Erkki I Ruoslahti's relentless pursuit of innovation and his profound impact on the field of biotechnology and medical research solidify his position as a visionary inventor whose work continues to shape the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…